Meira G Tx
Biotechnology, 450 E 29th St Fl 14, City, New York, 10016, United States, 51-200 Employees
Phone Number: 16*********
Who is MEIRAGTX
MeiraGTx is a gene therapy company with end-to-end capabilities in gene therapy discovery, development and GMP manufacturing. The company currently has 6 clinical programs, including one ...
Read More
-
Headquarters: 450 E 29th St Fl 14, New York City, New York, 10016, United States
-
Date Founded: 2015
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
Zandy Forbes
Email
Phone
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 32 |
Show More
MeiraGTx Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding MeiraGTx
Answer: MeiraGTx's headquarters are located at 450 E 29th St Fl 14, City, New York, 10016, United States
Answer: MeiraGTx's phone number is 16*********
Answer: MeiraGTx's official website is https://meiragtx.com
Answer: MeiraGTx's revenue is $10 Million to $25 Million
Answer: MeiraGTx's SIC: 2836
Answer: MeiraGTx's NAICS: 32
Answer: MeiraGTx has 51-200 employees
Answer: MeiraGTx is in Biotechnology
Answer: MeiraGTx contact info: Phone number: 16********* Website: https://meiragtx.com
Answer: MeiraGTx is a gene therapy company with end-to-end capabilities in gene therapy discovery, development and GMP manufacturing. The company currently has 6 clinical programs, including one in a pivotal study. In addition, MeiraGTx has two wholly owned GMP manufacturing facilities, a leading proprietary manufacturing platform process, large scale GMP plasmid production as well as in-house fill and finish and QC for stability and release. This infrastructure supports multiple clinical programs from IND through commercialization. MeiraGTx has also built industry-leading vectorology capabilities including optimization of all viral vector elements, with multiple discovery platforms from de-novo construction thorough AI driven in silico design. MeiraGTx has also developed a transformative riboswitch technology that tightly controls transgene expression in response to bespoke oral small molecules. This technology allows, for the first time, precise control of any transgene in any context based on the dose of a small molecule, which provides enormous potential for expanding the possibilities in genetic medicines today.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month